Business Wire

Elanco Animal Health and Farm Radio International Partner to Drive Change for Small-Scale Livestock Farmers in North Tanzania

Del

Elanco Animal Health Incorporated (NYSE:ELAN) and Farm Radio International (FRI) have partnered to produce a 13-week series of radio programs designed to support and educate small-scale livestock farmers in North Tanzania to manage the challenges around livestock health and wellbeing, supporting a drive to greater food security, livestock health and care in the region.

FRI and Elanco are working closely with local radio stations - Sauti ya Injili and Loliondo FM - to produce a short series of interactive radio programs, enabling listeners to make informed decisions, and have access to relevant animal health care products and training. The project aims to use radio to reach a widespread, rural population which has little access to agricultural services and reaching women who are crucial in livestock keeping. At the same time, FRI supports and develops the local broadcasters with training support during the production and airing phases of the agricultural programs.

The programs are currently being aired until December 14 th 2018 as follows:

  • Radio Sauti ya Injili for Kilimanjaro and Tanga with the frequencies 93.6 FM in Moshi every Thursday from 7:30 to 8:00 pm and repeats on Monday 6:00 to 6:30 pm.
  • Loliondo FM with the frequency 107.7 airs every Tuesday from 8:00 to 8:30 pm and repeats on Saturday 8:00 to 8:30 pm.

Elanco’s support of the radio campaign with FRI forms part of a ground-breaking project to provide sustainable development solutions to address food insecurity in East African countries – Tanzania, Kenya and Uganda. The East Africa Growth Accelerator (EAGA) is Elanco’s first pure ‘Shared Value’ project which is made possible through a $3.1 million grant from the Bill & Melinda Gates foundation. The grant enables the registration, manufacturing and distribution of affordable high-quality veterinary products, along with intensive training initiatives for smallholder farmers and channel partners.

“By working with FRI, Elanco aims to support improved animal husbandry and health practices and effect behaviour change by sharing information through the powerful medium of radio. The 13-week series will focus on knowledge transfer on disease awareness, prevention and treatment, including important topics such as fly, tick and rodent control, Coccidiosis, Mycoplasmosis, poultry vaccination and product training facilitated by Elanco,” explains Maria Zampaglione, Elanco One Health and Shared Value advisor and project leader.

Livestock disease remains a significant threat to achieving food security in East Africa where currently 25 percent of protein from farm animals is lost due to animal illness1, reducing the supply of high-quality milk, meat and eggs and creating significant economic losses for farmers.

According to the Food and Agriculture Organization (FAO) of the United Nations (UN), 34 percent of the people in East Africa are undernourished2.

“We think that radio presents a major opportunity to scale the important work of Elanco on livestock keeping. We really want to go beyond a simple one-way radio broadcast and instead build the capacity of local radio stations to produce interactive radio programs that are truly entertaining, two-way, and practical for the listening audience. We know livestock health is a topic that is crucial to the North of Tanzania and we are thrilled to have programs on the air to support small-scale livestock farmers in the region,” says Mark Leclair, Farm Radio International’s Manager of Communications.

Elanco’s goal through EAGA is to enable more than 240,000 dairy and poultry smallholder farmers to access small sized quality products by 2020. The grant from the Bill & Melinda Gates foundation further helps achieve this goal of improving the lives of smallholder farmers through sustainable livestock production.

Learn more about Elanco's commitment to “Making a Difference” and the EAGA Shared Value project at Elanco.com.

References:

1 - African Union Inter-African Bureau for Animal resources (AU-IBAR). Impact of livestock diseases in Africa. Published on 25 January 2013. Accessed on 1st June 2018 on http://www.au-ibar.org/vacnada-livestock-diseases?showall=1&limitstart

2 - FAO. 2017. Regional Overview of Food Security and Nutrition in Africa 2017. The food security and nutrition–conflict nexus: building resilience for food security, nutrition and peace. Accra. Accessed on 9th October 2018 on http://www.fao.org/3/a-i7967e.pdf.

About Elanco Animal Health

Elanco (NYSE: ELAN) is a global animal health company that develops products and knowledge services to prevent and treat disease in food animals and pets in more than 90 countries. With a 64-year heritage, we rigorously innovate to improve the health of animals and benefit our customers, while fostering an inclusive, cause-driven culture for more than 5,800 employees. At Elanco, we’re driven by our vision of food and companionship enriching life – all to advance the health of animals, people and the planet. Learn more at www.elanco.com.

About Farm Radio International

Farm Radio International is an international non-profit organization dedicated exclusively to serving African farming families and rural communities through radio. FRI currently works with more than 780 radio partners in 40 sub-Saharan African countries to fight poverty and food insecurity through high-quality radio programs that help small-scale African farmers help themselves. The radio station reaches tens of millions of small-scale farmers with life-changing information and opportunities to have a stronger voice in their own development, by providing a range of radio resources and training opportunities and working directly with select broadcasting partners on impact projects. Since 2007, FRI has worked with over 100 radio stations implementing more than 110 projects reaching more than 30 million farmers with interactive radio programming. Farm Radio International supports rural agricultural and economic development initiatives to communicate with small-scale farmers and rural households and support their efforts to innovate and affect change. www.farmradio.org.

Contact information

Media:
Karin Gerbens
+ 32 476 97 8467
gerbens_karin@elanco.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Pioneering Project for Pharmaceutics – Vifor Pharma and the University of Basel are Jointly Establishing the World’s First Research Professorship for Nanopharmaceutical and Regulatory Science26.5.2019 07:00:00 CESTPressemelding

Nanopharmaceutics promises ground-breaking innovation in the development of medicines: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190526005014/en/ The Vifor Pharma Group is endowing two professorships for Nanopharmaceutical and Regulatory Science at the University of Basel The commitment by Vifor Pharma and the University of Basel is aimed at ensuring Switzerland has the specialist knowledge and equipment needed to compete globally in this important emerging area of life sciences With this decision, Vifor Pharma is demonstrating its commitment to Switzerland as a world-leading location for pharmaceutical research and development Nanomedicines are playing an increasingly important role in the development of innovative new medications. These drugs are able to overcome specific cellular barriers in the human body with a view to targeting their effect even more precisely. Nanopharmacy therefore promises to help advance medic

XINHUANET: Promotion Event of The Most Beautiful Shooting Location in China Held During Cannes Film Festival25.5.2019 18:20:00 CESTPressemelding

On May 16 (local time), an event was held at the 72nd Cannes Film Festival to recommend China’s most beautiful shooting locations on the theme of “Fascinating China.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190525005008/en/ The representative from Cannes Convention Bureau (1st L), Michel Chevillon (C), vice president of the French Riviera Chamber of Commerce and Industry and head of hotel association, and Adeline CHAUVEAU (3rd R), officer in charge of film and television projects from French Embassy to China, pose for a group photo with the representatives from the cities awarded for "The most beautiful shooting location in China." (Photo: Business Wire) In the event, the Yellow Sea National Forest Park in Dongtai, Jiangsu Province, the One Hundred Mile Azalea Forest in Bijie, Guizhou Province, Siming District of Xiamen, Fujian Province, and the Li Autonomous County in Lingshui, Hainan Province were on the list. The p

Knopp Biosciences Presents Positive Preclinical Data for Lead Neonatal Epilepsy Drug Candidate at 2019 Antiepileptic Drug and Device Trials XV Conference24.5.2019 14:00:00 CESTPressemelding

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today presented in vitro and in vivo data for the company’s lead molecule for the targeted treatment of KCNQ2-neonatal epileptic encephalopathy (KCNQ2-NEE) at the Antiepileptic Drug and Device Trials XV Conference in Miami, Florida. KCNQ2-NEE, a rare infant genetic epilepsy, results from mutations in genes encoding the Kv7.2/Kv7.3 ion channel, leading to frequent seizures and profound developmental delay. The preclinical data were presented by Steven Dworetzky, Ph.D., Knopp’s Chief Scientific Officer, a longtime Kv7 researcher who led the group that first cloned the Kv7.2 and Kv7.3 genes during his former tenure with the Bristol-Myers Squibb Co. Dr. Dworetzky presented results demonstrating the in vitro nanomolar activity of KB-3061 and its significant seizure protection in the maximal electroshock mo

Accelerate Your Business in South Korea Through 2019 K-Startup Grand Challenge24.5.2019 10:20:00 CESTPressemelding

Entrepreneurs from across the globe should set their sights on participating in the 2019 K-Startup Grand Challenge. Supported by the Ministry of SMEs and Startups and National IT Industry Promotion Agency (NIPA) of South Korea, the initiative provides invaluable support and comprehensive resources to early age startups. Applications for the K-Startup Grand Challenge are currently being accepted through June 14, 2019. In order to advance in the program, teams must pass a regional audition. A judging panel of startup ecosystem experts and Korean accelerators will select 40 teams to participate in an enriching 3.5 month-long acceleration program in Korea. The selected teams will have exclusive access to free office space at the Startup Campus in Pangyo Techno Valley, one-on-one mentoring, information sessions, coaching on Korean and Asian business culture and the chance to attend insightful seminars on accounting regulations to tax laws, patents and more. Opportunities for networking with

New Investigational Clinical Data for Ipsen’s Oncology Products in 11 Solid Tumor Types to Be Presented at 2019 ASCO Annual Meeting24.5.2019 05:00:00 CESTPressemelding

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that new data from clinical studies on investigational uses of cancer medicines cabozantinib (Cabometyx®), liposomal irinotecan (Onivyde®), and lanreotide autogel (Somatuline®, marketed as Somatuline Depot® in the United States) will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting takes place in Chicago, Illinois, U.S., 31 May–4 June 2019; data featuring Ipsen medicines includes: New data from the Phase 3 CELESTIAL trial on the association of adverse events with efficacy outcomes for cabozantinib in patients with advanced hepatocellular carcinoma Overview of the Phase 3 COSMIC-312 trial of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma who have not received previous systemic anticancer therapy First Phase 2 data from the CaboGIST study (trial 1317) from the European Organization for Research and Treatment of

The Posiflex Group Showcases an Ecosystem of Connected Solution Endpoints with IoT Remote Monitoring at Computex 201924.5.2019 01:00:00 CESTPressemelding

For the Computex 2019 show, The Posiflex Group is featuring leading solution technology from the family of brands as a fully Serviced IoT Ecosystem. Solution end points include: Connected Modular Kiosks, POS Terminals, and Digital Signage solutions from Posiflex and KIOSK Information Systems Smart Medical Displays with gesture controls from Portwell Connected Gaming Solutions with Player Tracking Technology from Portwell subsidiary, Ganlot The booth display is based on common field service endpoints represented in a European Manor Destination Resort setting. Field solutions for an array of vertical market applications include QSR ordering, cinema ticketing, fashion retail customer loyalty, interactive signage, hotel / medical center check-in and bill pay, as well as casino gaming technology. This year, in addition to their renowned POS product suite, Posiflex will be featuring newly introduced Modular Kiosk platforms (co-designed by KIOSK and Posiflex), which are configure-to-order sta